Sean X Luo1, Diana Martinez2, Kenneth M Carpenter2, Mark Slifstein2, Edward V Nunes2. 1. Division of Substance Abuse, Department of Psychiatry, New York State Psychiatric Institute, Columbia University, Box 83, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: xsl2101@columbia.edu. 2. Division of Substance Abuse, Department of Psychiatry, New York State Psychiatric Institute, Columbia University, Box 83, 1051 Riverside Drive, New York, NY 10032, USA.
Abstract
BACKGROUND: Developing personalized treatments for cocaine dependence remains a significant clinical challenge. Positron emission tomography (PET) has shown that the [(11)C]raclopride signal in the ventral striatum is associated with treatment success in a positively reinforced contingency management program. The present study investigates whether this signal can be used to predict treatment outcome at an individual level. METHODS: Predictive models were developed using PET signals from 5 regions of the striatum and follow-up data in 24 patients, and evaluated using cross-validation. RESULTS: The ventral striatal PET signal alone can predict individual treatment response with a substantial degree of accuracy (cross-validated correct rate=82%). Incorporating information from other regions-of-interest (ROIs) in the striatum does not improve predictive performance, except for a small improvement with adding the posterior caudate. The addition of baseline demographic variables, including baseline severity measures, does not improve predictive performance. On the other hand, early treatment response and motivation, reflected by cumulative clinic attendance, performs as well as the PET signal (83%) by week 3 in the 24-week study. The combined model with both PET signals and cumulative clinic attendance demonstrates a significant improvement of performance, peaking at 96% during week 3 of the trial. CONCLUSIONS: These results suggest that a multimodal model can predict treatment success in cocaine dependence at an individual level, and pose hypotheses for the underlying neural circuitry mechanisms responsible for individual variations in treatment outcome. Published by Elsevier Ireland Ltd.
BACKGROUND: Developing personalized treatments for cocaine dependence remains a significant clinical challenge. Positron emission tomography (PET) has shown that the [(11)C]raclopride signal in the ventral striatum is associated with treatment success in a positively reinforced contingency management program. The present study investigates whether this signal can be used to predict treatment outcome at an individual level. METHODS: Predictive models were developed using PET signals from 5 regions of the striatum and follow-up data in 24 patients, and evaluated using cross-validation. RESULTS: The ventral striatal PET signal alone can predict individual treatment response with a substantial degree of accuracy (cross-validated correct rate=82%). Incorporating information from other regions-of-interest (ROIs) in the striatum does not improve predictive performance, except for a small improvement with adding the posterior caudate. The addition of baseline demographic variables, including baseline severity measures, does not improve predictive performance. On the other hand, early treatment response and motivation, reflected by cumulative clinic attendance, performs as well as the PET signal (83%) by week 3 in the 24-week study. The combined model with both PET signals and cumulative clinic attendance demonstrates a significant improvement of performance, peaking at 96% during week 3 of the trial. CONCLUSIONS: These results suggest that a multimodal model can predict treatment success in cocaine dependence at an individual level, and pose hypotheses for the underlying neural circuitry mechanisms responsible for individual variations in treatment outcome. Published by Elsevier Ireland Ltd.
Authors: P K Thanos; N D Volkow; P Freimuth; H Umegaki; H Ikari; G Roth; D K Ingram; R Hitzemann Journal: J Neurochem Date: 2001-09 Impact factor: 5.372
Authors: Katherine S Button; John P A Ioannidis; Claire Mokrysz; Brian A Nosek; Jonathan Flint; Emma S J Robinson; Marcus R Munafò Journal: Nat Rev Neurosci Date: 2013-04-10 Impact factor: 34.870
Authors: K M Kampman; A I Alterman; J R Volpicelli; I Maany; E S Muller; D D Luce; E M Mulholland; A F Jawad; G A Parikh; F D Mulvaney; R M Weinrieb; C P O'Brien Journal: Psychol Addict Behav Date: 2001-03
Authors: A Breier; T P Su; R Saunders; R E Carson; B S Kolachana; A de Bartolomeis; D R Weinberger; N Weisenfeld; A K Malhotra; W C Eckelman; D Pickar Journal: Proc Natl Acad Sci U S A Date: 1997-03-18 Impact factor: 11.205
Authors: Soyoung Q Park; Thorsten Kahnt; Anne Beck; Michael X Cohen; Raymond J Dolan; Jana Wrase; Andreas Heinz Journal: J Neurosci Date: 2010-06-02 Impact factor: 6.167
Authors: K Kampman; J R Volpicelli; A Alterman; J Cornish; R Weinrieb; L Epperson; T Sparkman; C P O'Brien Journal: Drug Alcohol Depend Date: 1996-05 Impact factor: 4.492
Authors: Rajesh Narendran; Savannah Tollefson; Michael L Himes; Jennifer Paris; Brian Lopresti; Roberto Ciccocioppo; N Scott Mason Journal: Am J Psychiatry Date: 2019-05-06 Impact factor: 18.112
Authors: Hestia Moningka; Sarah Lichenstein; Patrick D Worhunsky; Elise E DeVito; Dustin Scheinost; Sarah W Yip Journal: Neuropsychopharmacology Date: 2018-10-03 Impact factor: 7.853
Authors: C E Wiers; E Shumay; E Cabrera; E Shokri-Kojori; T E Gladwin; E Skarda; S I Cunningham; S W Kim; T C Wong; D Tomasi; G-J Wang; N D Volkow Journal: Transl Psychiatry Date: 2016-03-08 Impact factor: 6.222